Exclusive

Publication

Byline

Location

Clinical Trial: A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07748624) titled 'A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants Wi... Read More


Singapore Clinical Trial: A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center study, with a primary efficacy endpoint at 12 weeks, to determine the efficacy, safety, and tolerability of fixed doses of 15 mg bid and 30 mg bid of evenamide as add-on in patients with documented treatment-resistant schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient’s current antipsychotic medication(s).

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, mu... Read More


Clinical Trial: Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07749924) titled 'Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-S... Read More


Singapore Clinical Trial: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab ... Read More


Clinical Trial: A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07749586) titled 'A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Soli... Read More


Clinical Trial: LIVER STEATOSIS AND FIBROSIS IN NON-CELIAC WHEAT SENSITIVITY PATIENTS: A PROSPECTIVE STUDY

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07750535) titled 'LIVER STEATOSIS AND FIBROSIS IN NON-CELIAC WHEAT SENSITIVITY PATIENTS: A PROSPECTIVE STUDY' ... Read More


Clinical Trial: SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07748611) titled 'SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable... Read More


Clinical Trial: Virtual Reality Exergaming During Work Breaks in Office Employees

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07749196) titled 'Virtual Reality Exergaming During Work Breaks in Office Employees' on Aug. 01. Brief Summar... Read More


Clinical Trial: One-year Clinical Outcomes of Endoscopic Cardia Banding Plication for Refractory Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07749352) titled 'One-year Clinical Outcomes of Endoscopic Cardia Banding Plication for Refractory Gastroesoph... Read More


Clinical Trial: Predicting Response and Exposure Changes in Cirrhosis for Effectiveness

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07750587) titled 'Predicting Response and Exposure Changes in Cirrhosis for Effectiveness' on Aug. 03. Brief ... Read More